These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 8882316)
21. Antibodies and resistance to natural HIV infection. Nabel GJ; Sullivan NJ N Engl J Med; 2000 Oct; 343(17):1263-5. PubMed ID: 11071680 [No Abstract] [Full Text] [Related]
22. Prospects for vaccine protection against HIV-1 infection and AIDS. Letvin NL; Barouch DH; Montefiori DC Annu Rev Immunol; 2002; 20():73-99. PubMed ID: 11861598 [TBL] [Abstract][Full Text] [Related]
23. First updated and revised survey of worldwide HIV and SIV vaccine challenge studies in nonhuman primates: progress in first and second order studies. Warren JT; Dolatshahi M J Med Primatol; 1993; 22(2-3):203-35. PubMed ID: 8411110 [No Abstract] [Full Text] [Related]
24. [Progress in vaccination against AIDS]. Burny A Bull Mem Acad R Med Belg; 1995; 150(3-4):145-53; discussion 153-5. PubMed ID: 8845793 [TBL] [Abstract][Full Text] [Related]
25. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321 [TBL] [Abstract][Full Text] [Related]
26. Current world literature. Curr Opin HIV AIDS; 2012 Jan; 7(1):86-95. PubMed ID: 22156801 [No Abstract] [Full Text] [Related]
35. Monkey business over AIDS vaccine. Weiss R BMJ; 1991 Oct; 303(6807):872. PubMed ID: 1933002 [No Abstract] [Full Text] [Related]
36. AIDS 1995. Vaccines and immunology: overview. Montelaro RC; Wigzell H AIDS; 1995; 9 Suppl A():S111-2. PubMed ID: 8819577 [No Abstract] [Full Text] [Related]
37. Evaluation of recombinant Kunjin replicon SIV vaccines for protective efficacy in macaques. Kent SJ; De Rose R; Mokhonov VV; Mokhonova EI; Fernandez CS; Alcantara S; Rollman E; Mason RD; Loh L; Peut V; Reece JC; Wang XJ; Wilson KM; Suhrbier A; Khromykh A Virology; 2008 May; 374(2):528-34. PubMed ID: 18272194 [TBL] [Abstract][Full Text] [Related]
38. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques. Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630 [TBL] [Abstract][Full Text] [Related]
39. Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model. Nehete PN; Nehete BP; Manuri P; Hill L; Palmer JL; Sastry KJ Vaccine; 2005 Mar; 23(17-18):2154-9. PubMed ID: 15755586 [TBL] [Abstract][Full Text] [Related]
40. CTL ontogeny and viral escape: implications for HIV-1 vaccine design. Yang OO Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]